Goldman Ismail Helps Merck Secure Patent Infringement Victory
Goldman Ismail recently secured a victory for Merck in the U.S. District Court for the District of New Jersey affirming and validating Merck’s U.S. patent protection for Bridion through January 2026. Merck hired Goldman Ismail to serve as lead trial counsel in patent infringement suits under the Hatch-Waxman Act. The suits arose out of Abbreviated New Drug Applications filed by over a dozen manufacturers seeking approval to make and sell a generic version of Merck’s Bridion product, a reversal agent for neuromuscular blockers administered during anesthesia.
A Goldman Ismail team (Shayna Cook, Alan Littmann, Doug Winnard, Michael Casner, and Lesley Hamming) partnered with co-counsel Jones Day to secure Merck’s victory. The Court’s decision can be read here.